[go: up one dir, main page]

SI2997035T1 - 11-hidroksil-6-substituirani-derivati žolčnih kislin in amino kislinski konjugati le-teh, kot modulatorji farnezoidnega x receptorja - Google Patents

11-hidroksil-6-substituirani-derivati žolčnih kislin in amino kislinski konjugati le-teh, kot modulatorji farnezoidnega x receptorja

Info

Publication number
SI2997035T1
SI2997035T1 SI201430701T SI201430701T SI2997035T1 SI 2997035 T1 SI2997035 T1 SI 2997035T1 SI 201430701 T SI201430701 T SI 201430701T SI 201430701 T SI201430701 T SI 201430701T SI 2997035 T1 SI2997035 T1 SI 2997035T1
Authority
SI
Slovenia
Prior art keywords
farnesoid
hydroxyl
derivatives
substituted
amino acid
Prior art date
Application number
SI201430701T
Other languages
English (en)
Inventor
Roberto Pellicciari
Original Assignee
Intercept Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50721801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2997035(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals, Inc. filed Critical Intercept Pharmaceuticals, Inc.
Publication of SI2997035T1 publication Critical patent/SI2997035T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201430701T 2013-05-14 2014-05-14 11-hidroksil-6-substituirani-derivati žolčnih kislin in amino kislinski konjugati le-teh, kot modulatorji farnezoidnega x receptorja SI2997035T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361823169P 2013-05-14 2013-05-14
EP14723820.8A EP2997035B8 (en) 2013-05-14 2014-05-14 11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
PCT/EP2014/059896 WO2014184271A1 (en) 2013-05-14 2014-05-14 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators

Publications (1)

Publication Number Publication Date
SI2997035T1 true SI2997035T1 (sl) 2018-10-30

Family

ID=50721801

Family Applications (3)

Application Number Title Priority Date Filing Date
SI201430701T SI2997035T1 (sl) 2013-05-14 2014-05-14 11-hidroksil-6-substituirani-derivati žolčnih kislin in amino kislinski konjugati le-teh, kot modulatorji farnezoidnega x receptorja
SI201431741T SI3360882T1 (sl) 2013-05-14 2014-05-14 11-hidroksil-6-substituirani derivati žolčnih kislin in aminokislinski konjugati le-teh kot modulatorji receptorja farnezoid X
SI201431742T SI3360881T1 (sl) 2013-05-14 2014-05-14 11-hidroksil-6-substituirani derivati žolčnih kislin in aminokislinski konjugati le-teh kot modulatorji receptorja farnezoid X

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI201431741T SI3360882T1 (sl) 2013-05-14 2014-05-14 11-hidroksil-6-substituirani derivati žolčnih kislin in aminokislinski konjugati le-teh kot modulatorji receptorja farnezoid X
SI201431742T SI3360881T1 (sl) 2013-05-14 2014-05-14 11-hidroksil-6-substituirani derivati žolčnih kislin in aminokislinski konjugati le-teh kot modulatorji receptorja farnezoid X

Country Status (38)

Country Link
US (7) US9611289B2 (sl)
EP (4) EP2997035B8 (sl)
JP (2) JP6326131B2 (sl)
KR (1) KR102229952B1 (sl)
CN (2) CN108245523B (sl)
AU (1) AU2014267324B2 (sl)
BR (1) BR112015028399B1 (sl)
CA (1) CA2912139C (sl)
CL (2) CL2015003344A1 (sl)
CR (1) CR20150643A (sl)
CY (1) CY1122614T1 (sl)
DK (4) DK3360881T3 (sl)
EA (1) EA030152B1 (sl)
ES (4) ES2847002T3 (sl)
GT (1) GT201500324A (sl)
HK (2) HK1253326A1 (sl)
HR (1) HRP20180931T1 (sl)
HU (1) HUE037996T2 (sl)
IL (2) IL242555B (sl)
LT (1) LT2997035T (sl)
MA (1) MA38647B1 (sl)
ME (1) ME03082B (sl)
MX (1) MX352065B (sl)
MY (1) MY187886A (sl)
NI (1) NI201500160A (sl)
PE (1) PE20160665A1 (sl)
PH (1) PH12015502576B1 (sl)
PL (3) PL3360882T3 (sl)
PT (3) PT2997035T (sl)
RS (1) RS57372B1 (sl)
SA (1) SA515370140B1 (sl)
SG (1) SG11201509352XA (sl)
SI (3) SI2997035T1 (sl)
SM (1) SMT201800326T1 (sl)
TN (1) TN2015000497A1 (sl)
TR (1) TR201809041T4 (sl)
UA (1) UA118673C2 (sl)
WO (1) WO2014184271A1 (sl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157816A0 (en) 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CN108245523B (zh) 2013-05-14 2021-03-26 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11-羟基衍生物及其氨基酸共轭物
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
LT3626725T (lt) 2014-05-29 2023-03-10 Bar Pharmaceuticals S.R.L. Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
CA2968305A1 (en) 2014-11-19 2016-05-26 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
BR112017010319B1 (pt) 2014-11-19 2023-04-11 NZP UK Limited Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
MX381239B (es) 2014-11-19 2025-03-12 Nzp Uk Ltd Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
JP6724004B2 (ja) 2014-11-19 2020-07-15 エヌゼットピー ユーケー リミテッド ステロイドＦＸＲモジュレーター製造のための中間体としての５β−６−アルキル−７−ヒドロキシ−３−オンステロイド
MX2017006833A (es) 2014-11-26 2018-02-13 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
MA41094A (fr) * 2014-12-02 2017-10-10 Lilly Co Eli Procédés de traitement de troubles rénaux
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN104523703A (zh) * 2014-12-24 2015-04-22 聂飚 一种游离脂肪酸转运蛋白小分子抑制物的应用
DK3253382T3 (da) * 2015-02-06 2022-02-14 Intercept Pharmaceuticals Inc Farmaceutiske sammensætninger til kombinationsterapi
SG11201706089RA (en) 2015-02-11 2017-09-28 Enanta Pharm Inc Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN107530361A (zh) * 2015-03-09 2018-01-02 英特塞普特医药品公司 用于调节骨密度的方法
WO2016145216A1 (en) * 2015-03-10 2016-09-15 Metselex, Inc. Fluorinated and alkylated bile acids
CA2979399A1 (en) * 2015-03-13 2016-09-22 Salk Institute For Biological Studies Treating latent autoimmune diabetes of adults with farnesoid x receptor agonists to activate intestinal receptors
SMT202100593T1 (it) * 2015-03-31 2021-11-12 Enanta Pharm Inc Derivati degli acidi biliari come agonisti di fxr/tgr5 e metodi per il loro uso
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
WO2016168553A1 (en) * 2015-04-17 2016-10-20 Concert Pharmaceuticals, Inc. Deuterated obeticholic acid
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN106478759A (zh) * 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN108348543A (zh) * 2015-09-21 2018-07-31 英特塞普特医药品公司 促进肝再生的方法
BR112018006892B1 (pt) * 2015-10-07 2023-04-11 Intercept Pharmaceuticals, Inc Composto, composição farmacêutica do mesmo e seus usos como moduladores do receptor farnesoide x
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) * 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
EA038632B1 (ru) * 2016-03-11 2021-09-27 Интерсепт Фармасьютикалз, Инк. 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr)
KR102377338B1 (ko) * 2016-04-13 2022-03-21 인터셉트 파마슈티컬즈, 인크. 암의 치료 방법
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
MX2018015443A (es) 2016-06-13 2019-04-11 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA3045023A1 (en) 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
JP7618384B2 (ja) 2017-02-21 2025-01-21 ジェンフィ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
WO2018156916A2 (en) * 2017-02-23 2018-08-30 Intercept Pharmaceuticals, Inc Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof
AU2018243719B2 (en) 2017-03-28 2021-01-21 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
AU2018249950B2 (en) 2017-04-07 2023-09-21 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
WO2018226724A1 (en) * 2017-06-05 2018-12-13 Intercept Pharmaceuticals, Inc. Treatment and prevention of diabetic eye diseases with a bile acid derivatives
CA3067219A1 (en) * 2017-06-23 2018-12-27 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives
CA3070837A1 (en) 2017-07-24 2019-01-31 Intercept Pharmaceuticals, Inc. Isotopically labeled bile acid derivatives
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN109182451B (zh) * 2018-08-21 2021-06-11 四川大学 细胞色素cyp3a7酶的新型特异性探针反应及其应用
CA3124702A1 (en) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
SG11202113155XA (en) * 2019-05-30 2021-12-30 Intercept Pharmaceuticals Inc Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
CN110540955B (zh) * 2019-08-28 2021-09-17 北京协同创新研究院 一种提高分化细胞中nrob2基因表达量的方法
US20230060715A1 (en) 2020-01-15 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
CN117202905A (zh) 2021-01-14 2023-12-08 埃尼奥制药公司 Fxr激动剂和ifn用于治疗hbv感染的协同效果
EP4329761A1 (en) 2021-04-28 2024-03-06 ENYO Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
WO2022233398A1 (en) * 2021-05-04 2022-11-10 Kostner Pharma Gmbh COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
WO2023288123A1 (en) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2080775A (en) * 1934-08-22 1937-05-18 Celanese Corp Shedding mechanism for circular looms
US2802775A (en) * 1953-05-29 1957-08-13 Merck & Co Inc 11 alpha-hydroxylation of steroids by aspergillus ochraceus
JPS59205396A (ja) * 1983-05-09 1984-11-20 Kuraray Co Ltd １１β−ヒドロキシプレグナ−４−エン−３−オン−２０−カルブアルデヒド及びその製造法
CA2356887A1 (en) 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
ITMI20021532A1 (it) * 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
PT1734970E (pt) * 2004-03-12 2015-03-11 Intercept Pharmaceuticals Inc Tratamento de fibrose utilizando ligandos de rfx
US7932244B2 (en) * 2006-06-27 2011-04-26 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
CN108245523B (zh) 2013-05-14 2021-03-26 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11-羟基衍生物及其氨基酸共轭物

Also Published As

Publication number Publication date
KR20160007586A (ko) 2016-01-20
EA201592055A1 (ru) 2016-11-30
ES2843737T3 (es) 2021-07-20
CN105377870A (zh) 2016-03-02
PT3360882T (pt) 2021-02-12
CL2015003344A1 (es) 2016-07-15
AU2014267324B2 (en) 2017-11-02
US20230233581A1 (en) 2023-07-27
AU2014267324A1 (en) 2015-11-26
US10532061B2 (en) 2020-01-14
ES2671427T3 (es) 2018-06-06
HUE037996T2 (hu) 2018-09-28
SI3360882T1 (sl) 2021-06-30
PH12015502576A1 (en) 2016-02-29
DK3360881T3 (da) 2021-03-15
LT2997035T (lt) 2018-08-10
DK3360882T3 (da) 2021-03-08
EP3360881A1 (en) 2018-08-15
CY1122614T1 (el) 2020-07-31
TR201809041T4 (tr) 2018-07-23
CN108245523B (zh) 2021-03-26
MA38647B1 (fr) 2019-05-31
UA118673C2 (uk) 2019-02-25
CA2912139A1 (en) 2014-11-20
DK3848038T3 (da) 2023-02-06
DK2997035T3 (en) 2018-07-02
HRP20180931T1 (hr) 2018-10-05
EP2997035B8 (en) 2018-05-23
EP3360882B1 (en) 2020-12-09
PL2997035T3 (pl) 2018-10-31
SMT201800326T1 (it) 2018-07-17
KR102229952B1 (ko) 2021-03-22
NZ714082A (en) 2021-02-26
US20210228599A1 (en) 2021-07-29
CN105377870B (zh) 2018-04-03
IL242555A0 (en) 2016-02-01
EP3360881B1 (en) 2020-12-09
IL272718A (en) 2020-04-30
TN2015000497A1 (en) 2017-04-06
CN108245523A (zh) 2018-07-06
ES2936638T3 (es) 2023-03-21
SG11201509352XA (en) 2015-12-30
CA2912139C (en) 2021-04-20
NI201500160A (es) 2016-01-04
MX352065B (es) 2017-11-08
PH12015502576B1 (en) 2018-09-12
PL3360882T3 (pl) 2021-10-25
JP6326131B2 (ja) 2018-05-16
US11000532B2 (en) 2021-05-11
MY187886A (en) 2021-10-26
RS57372B1 (sr) 2018-08-31
EA030152B1 (ru) 2018-06-29
HK1253326A1 (zh) 2019-06-14
ME03082B (me) 2019-01-20
EP3848038B1 (en) 2022-11-09
JP2016518429A (ja) 2016-06-23
SA515370140B1 (ar) 2017-04-11
EP2997035B1 (en) 2018-03-28
WO2014184271A1 (en) 2014-11-20
PT2997035T (pt) 2018-07-18
US9611289B2 (en) 2017-04-04
PT3360881T (pt) 2021-02-19
BR112015028399A2 (pt) 2017-07-25
US20170216316A1 (en) 2017-08-03
HK1221471A1 (zh) 2017-06-02
EP3360882A1 (en) 2018-08-15
SI3360881T1 (sl) 2021-06-30
ES2847002T3 (es) 2021-07-30
EP2997035A1 (en) 2016-03-23
CR20150643A (es) 2016-06-01
IL242555B (en) 2020-04-30
GT201500324A (es) 2017-09-28
PL3360881T3 (pl) 2021-11-15
US20200297739A1 (en) 2020-09-24
IL272718B (en) 2020-11-30
PE20160665A1 (es) 2016-08-07
BR112015028399B1 (pt) 2021-11-16
CL2016001809A1 (es) 2017-01-27
JP2018127481A (ja) 2018-08-16
US20140371190A1 (en) 2014-12-18
US20240398834A1 (en) 2024-12-05
US20190209586A1 (en) 2019-07-11
EP3848038A1 (en) 2021-07-14

Similar Documents

Publication Publication Date Title
IL272718B (en) History of 11-hydroxyl of bile acids and their conjugates with amino acid as paranoid x receptor modulators
HRP20181269T1 (hr) Peptidi i sastavi za liječenje oštećenja zglobova
SG11201604697TA (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
HK1211295A1 (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof c17-
EP2804488A4 (en) METHOD OF INSTANCING AMINO ACIDS
IL227890A0 (en) Antiaging compounds containing bile acid and fatty acid conjugates
EP2970928A4 (en) Generation of acyl amino acids
EP3004132A4 (en) Bile acid-basic amino acid conjugates and uses thereof
EP2961264A4 (en) METHODS AND COMPOSITIONS FOR THE PREPARATION OF NUCLEIC ACIDS
TH1501006859A (th) อนุพันธ์ 11-ไฮดรอกซิลและกรดน้ำดีและสารควบคู่กรดอะมิโนของสิ่งนั้นในฐานะ ตัวควบคุมปรับสภาพฟาร์นีซอยด์ x รีเซพเตอร์